证券代码：300759 证券简称：康龙化成 公告编号：2025-028 康龙化成（北京）新药技术股份有限公司 关于召开 2024 年年度股东大会、2025 年第一次 A 股类别股 2、股东大会的召集人：公司董事会。 3、会议召开的合法、合规性：本次股东大会的召集、召开程序符合有关法 律、行政法规、部门规章、规范性文件和《公司章程》的规定。 4、会议召开的时间： （1）现场会议召开时间：2025 年 6 月 20 日（星期五）13:30； （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为 2025 年 6 月 20 日的交易时间，即 9:15-9:25，9:30-11:30 和 13:00-15:00；通 过深圳证券交易所互联网投票系统进行网络投票的具体时间为 2025 年 6 月 20 日 9:15-15:00。 5、会议的召开方式： 东大会及 2025 年第一次 H 股类别股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 经康龙化成（北京）新药技术股份有限公司（以下简称"公司"）于 2025 年 3 月 26 日召开的第 ...

Group 1 - The National Vaccine and Biotechnology Index (980015) has seen a strong increase of 2.39% as of May 29, 2025, with notable gains in constituent stocks such as Zhaoyan New Drug (603127) up 9.99%, Yifan Pharmaceutical (002019) up 9.17%, and Dizhe Pharmaceutical (688192) up 8.73% [1] - The Biovaccine ETF (159657) rose by 2.28%, with the latest price reported at 0.63 yuan [2] - The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting will take place from May 30 to June 3, 2025, in Chicago, showcasing the development of oncology research in China, with over 70 studies from Chinese scholars selected for presentation [2] Group 2 - The top ten weighted stocks in the National Vaccine and Biotechnology Index (980015) as of April 30, 2025, include Fosun Pharma (600196), Changchun High-tech (000661), and others, collectively accounting for 63.18% of the index [3] - The Biovaccine ETF closely tracks the National Vaccine and Biotechnology Index, which consists of 50 companies involved in the biotechnology industry, reflecting the overall performance of quality listed companies in the sector [2]

Group 1 - The core viewpoint is that the pharmaceutical industry is expected to experience stable growth driven by innovation, policy optimization, and increasing clinical demand due to aging demographics [3] - The National Biopharmaceutical Index (399441) has shown a strong increase of 1.83%, with key stocks like Kylin Pharmaceutical (002821) rising by 5.51% and Zhaoyan New Drug (603127) by 4.66% [1] - The Biopharmaceutical ETF (159839) has seen a cumulative increase of 1.54% over the past two weeks, indicating positive market sentiment [1] Group 2 - Open Source Securities emphasizes that the pharmaceutical sector will benefit from improved drug procurement policies and a favorable external environment, leading to a recovery in the healthcare industry [3] - Citic Securities notes that the pharmaceutical sector achieved its best market returns in the first half of 2025, driven by policy trends and the maturation of pharmaceutical innovation [3] - The current PEG levels for most growth-oriented pharmaceutical companies are below 1, suggesting potential for performance and valuation recovery [3]

Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Health Mixed Fund C, which has shown a recent net value increase and varying returns over different time frames [1] - As of May 27, 2025, the fund's latest net value is 1.5582 yuan, reflecting a growth of 0.85% [1] - The fund's one-month return is 3.03%, ranking 1106 out of 4652 in its category, while its six-month return is 0.23%, ranking 3299 out of 4496 [1] - Year-to-date, the fund has achieved a return of 2.43%, ranking 2140 out of 4544 [1] Group 2 - The top ten stock holdings of the fund account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%), WuXi AppTec (9.95%), and Kanglong Chemical (6.24%) [1] - The fund was established on September 29, 2016, and as of March 31, 2025, it has a total scale of 15.566 billion yuan [1] - The fund manager, Ge Lan, has a background in biomedical engineering and has held various positions in research and fund management since joining China Europe Fund Management in 2014 [2]

Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Health Mixed A Fund, which has seen a recent decline in net value and varying returns over different time frames [1] - As of May 26, 2025, the latest net value of the fund is 1.6119 yuan, reflecting a decrease of 1.60%. The fund's one-month return is 3.10%, six-month return is 0.62%, and year-to-date return is 2.75, with respective rankings of 937 out of 3909, 2718 out of 3796, and 1764 out of 3832 [1] - The top ten stock holdings of the fund account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%), WuXi AppTec (9.95%), and Mindray Medical (5.21%) [1] Group 2 - The China Europe Medical Health Mixed A Fund was established on September 29, 2016, and as of March 31, 2025, it has a total scale of 15.613 billion yuan. The fund manager is Ms. Ge Lan [1] - Ms. Ge Lan has a background in biomedical engineering with a Ph.D. from Northwestern University and has held various research and fund management positions since joining China Europe Fund Management in October 2014 [2]

Group 1 - The overall market experienced a decline in the afternoon, but the pharmaceutical and medical sectors showed resilience, with only three out of 31 industries reporting gains [1] - The representative medical ETF (512170) saw a daily increase of 0.62%, with a significant trading volume of 9.82 billion, marking a 128% increase from the previous day and the highest single-day trading volume in over a month and a half [2] - The CXO-related stocks were the main contributors to the sector's performance, with notable gains from companies like Tigermed, which rose by 5.64%, while major player WuXi AppTec experienced a decline [2] Group 2 - For the week of May 19-23, the medical ETF (512170) accumulated a gain of 1.24%, outperforming major indices such as the Shanghai Composite Index, which fell by 0.57% [4] - The market for medical stocks is gradually recovering, with increased trading activity and positive catalysts such as domestic pharmaceutical companies securing overseas contracts [4] - A new "Pharmaceutical ETF" is set to launch on May 26, which will track the CSI Pharmaceutical Index, focusing on chemical drugs, biological drugs, and traditional Chinese medicine, complementing the existing medical ETF [4] Group 3 - The medical and pharmaceutical sectors have been in a prolonged adjustment period since 2021, with current valuations potentially offering high cost-effectiveness for investors [4]

Core Insights - The ChiNext 50 Index (399673) has shown a slight increase of 0.29% as of May 23, 2025, with notable gains from stocks such as Tigermed (300347) up by 7.08% and Kanglong Chemical (300759) up by 4.50% [1][2] - The ChiNext 50 ETF (159367) has a recent price of 0.96 yuan, with a weekly increase of 0.52%, ranking 2nd out of 9 comparable funds [1] - The ETF has a low management fee of 0.15% and a custody fee of 0.05%, making it one of the most cost-effective options among comparable funds [1] Performance Metrics - The top ten weighted stocks in the ChiNext 50 Index account for 64.53% of the index, with Ningde Times (300750) holding the largest weight at 24.47% [2][4] - The ChiNext 50 ETF has an average daily trading volume of 605.42 million yuan over the past year, with a turnover rate of 1.59% on the latest trading day [1] - The price-to-book ratio (PB) of the ChiNext 50 Index is currently at 4.27, which is below the historical average for over 80.56% of the past five years, indicating a favorable valuation [1]

Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Health Mixed A Fund, which has shown a recent net value increase and varying returns over different time frames [1] - As of May 21, 2025, the latest net value of the fund is 1.6359 yuan, reflecting a growth of 1.36% [1] - The fund's one-month return is 4.85%, ranking 1834 out of 4645 in its category, while the three-month return is 0.17%, ranking 1678 out of 4590 [1] - Year-to-date, the fund has achieved a return of 4.28%, with a ranking of 2331 out of 4544 [1] Group 2 - The top ten stock holdings of the China Europe Medical Health Mixed A Fund account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%) and WuXi AppTec (9.95%) [1] - The fund was established on September 29, 2016, and as of March 31, 2025, it has a total scale of 15.613 billion yuan [1] - The fund manager, Ge Lan, has a background in biomedical engineering and has held various positions in research and fund management since joining China Europe Fund Management in 2014 [2]

Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Health Mixed Fund C, which has shown a recent net value increase and varying returns over different time frames [1] - As of May 20, 2025, the fund's latest net value is 1.5473 yuan, reflecting a growth of 2.76% [1] - The fund's one-month return is 5.29%, three-month return is 0.92%, and year-to-date return is 2.57%, with respective rankings of 3149 out of 4647, 1587 out of 4590, and 3094 out of 4546 [1] Group 2 - The top ten stock holdings of the fund account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%), WuXi AppTec (9.95%), and Kanglong Chemical (6.24%) [1] - The fund was established on September 29, 2016, and as of March 31, 2025, it has a total scale of 15.566 billion yuan [1] - The fund manager, Ge Lan, has a background in biomedical engineering and has held various positions in research and fund management since joining China Europe Fund Management in 2014 [2]

Group 1 - The major shareholder, Xincheng Kangcheng, plans to reduce its stake in Kanglong Chemical (300759) by up to 26.67 million shares, which represents 1.50% of the company's total share capital [1]